NCT03282149View on ClinicalTrials.gov

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

March 31, 2019

Study Completion Date

June 15, 2019

Conditions
Osteoarthritis, Knee
Interventions
BIOLOGICAL

XT-150

IL-10 transgene DNA plasmid injected into the knee synovial capsule

Trial Locations (1)

5005

CMAX Clinical Research Pty Ltd in collaboration with University of Adelaide, Adelaide

All Listed Sponsors
lead

Xalud Therapeutics, Inc.

INDUSTRY

NCT03282149 - Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain | Biotech Hunter | Biotech Hunter